载脂蛋白A5及载脂蛋白C3与冠心病的关系
摘要
血脂异常对冠心病发生发展有重要影响,血脂异常的实质是脂蛋白和载脂蛋白的异常,载脂蛋白作为脂蛋白中的蛋白质部分,对于血脂代谢及冠心病发生发展有重要影响。载脂蛋白A5与载脂蛋白C3对于血浆甘油三酯水平及冠心病发生发展起到独立但相反的作用,ApoA5和ApoC3基因多样性为目前研究热点。
引文
[1] Baroukh N,Bauge E,Akiyama J,et al.Analysis of apolipoprotein A5,c3,and plasma triglyceride concentrations in genetically engineered mice[J].Arterioscler Thromb Vasc Biol,2004,24(7):1297-1302.
[2] Van Der Vliet HN,Sammels MG,Leegwater AC,et al.Apolipoprotein A-V:a novel apolipoprotein associated with an early phase of liver regeneration[J].J Biol Chem,2001,276(48):44512-44520.
[3] Pennacchio LA,Olivier M,Hubacek JA,et al.An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing[J].Science,2001,294(5540):169-173.
[4] Havel RJ.Triglyceride-rich lipoproteins and plasma lipid transport[J].Arterioscler Thromb Vasc Biol,2010,30(1):9-19.
[5] O′brien PJ,Alborn WE,Sloan JH,et al.The novel apolipoprotein A5 is present in human serum,is associated with VLDL,HDL,and chylomicrons,and circulates at very low concentrations compared with other apolipoproteins[J].Clin Chem,2005,51(2):351-359.
[6] 何成毓,李洁琪.血清载脂蛋白A5与冠心病的关系[J].临床心血管杂志,2008,24(12):948-949.
[7] 杨轶文,陈焕芹,常静,等.冠心病患者血清载脂蛋白A5的变化及其与血脂和脂蛋白的关系[J].中国动脉硬化杂志,2006,14(12):1049-1052.
[8] 魏红霞,张葵,邱方,等.血清载脂蛋白 A5 水平与冠心病的关系[J].临床检验杂志,2010,28(7):276-278.
[9] 刘欢,李向平,赵水平,等.冠心病患者载脂蛋白A5与脂联素和空腹胰岛素的关系研究[J],中国实用内科杂志,2007,27(22):1767-1769.
[10] Cui G,Li Z,Li R,et al.A functional variant in APOA5/A4/C3/A1 gene cluster contributes to elevated triglycerides and severity of CAD by interfering with microRNA 3201 binding efficiency[J].J Am Coll Cardiol,2014,64(3):267-277.
[11] Kim M,Kim M,Yoo HJ,et al.A promoter variant of the APOA5 gene increases atherogenic LDL levels and arterial stiffness in hypertriglyceridemic patients[J].PLoS One,2017,12(12):e0186693.
[12] Takeuchi F,Isono M,Katsuya T,et al.Association of genetic variants influencing lipid levels with coronary artery disease in Japanese individuals[J].PLoS One,2012,7(9):e46385.
[13] Lin YC,Nunez V,Johns R,et al.APOA5 Gene Polymorphisms and Cardiovascular Diseases:Metaprediction in Global Populations[J].Nurs Res,2017,66(2):164-174.
[14] You Y,Wu YH,Zhang Y,et al.Effects of polymorphisms in APOA5 on the plasma levels of triglycerides and risk of coronary heart disease in Jilin,northeast China:a case-control study[J].BMJ Open,2018,8(6):e020016.
[15] Wang Y,Lu Z,Zhang J,et al.The APOA5 rs662799 polymorphism is associated with dyslipidemia and the severity of coronary heart disease in Chinese women[J].Lipids Health Dis,2016,15(1):170.
[16] Shou W,Wang Y,Xie F,et al.A functional polymorphism affecting the APOA5 gene expression is causally associated with plasma triglyceride levels conferring coronary atherosclerosis risk in Han Chinese Population[J].Biochim Biophys Acta,2014,1842(11):2147-2154.
[17] Kashyap S,Kumar S,Agarwal V,et al.The association of polymorphic variants,rs2267788,rs1333049 and rs2383207 with coronary artery disease,its severity and presentation in North Indian population[J].Gene,2018,648:89-96.
[18] Soufi M,Sattler AM,Kurt B,et al.Mutation screening of the APOA5 gene in subjects with coronary artery disease[J].J Investig Med,2012,60(7):1015-1019.
[19] 王瑾瑜.载脂蛋白CIII与高甘油三酯血症[J].生理科学进展,2010,41(1):37-39.
[20] Yang G,Lei MM,Yu CL,et al.Apolipoprotein A5 and apolipoprotein C3 single nucleotide polymorphisms are correlated with an increased risk of coronary heart disease:a case-control and meta-analysis study[J].Lipids Health Dis,2015,14:113.
[21] Sacks FM,Alaupovic P,Moye LA,et al.VLDL,apolipoproteins B,CIII,and E,and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial[J].Circulation,2000,102(16):1886-1892.
[22] Aroner SA,Koch M,Mukamal KJ,et al.High-Density Lipoprotein Subspecies Defined by Apolipoprotein C-III and Subclinical Atherosclerosis Measures:MESA (The Multi-Ethnic Study of Atherosclerosis)[J].J Am Heart Assoc,2018,7(6):e007824.
[23] Manfredi M,Chiariello C,Conte E,et al.Plasma proteome profiles of stable CAD patients stratified according to total apo C-III levels[J].Proteomics Clin Appl,2019,13(3):e1800023.
[24] Luo M,Su X,Yi Y,et al.Apolipoprotein CIII may mediate the impacts of angiopoietin-like protein 8 on triglyceride metabolism[J].Lipids Health Dis,2018,17(1):160.
[25] Xiong X,Liu H,Hua L,et al.The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it[J].Lipids Health Dis,2015,14:127.
[25] Luo M,Liu A,Wang S,et al.ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity[J].Sci Rep,2017,7(1):2312.
[27] Kawakami A,Aikawa M,Libby P,et al.Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells[J].Circulation,2006,113(5):691-700.
[28] Kawakami A,Aikawa M,Alcaide P,et al.Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells[J].Circulation,2006,114(7):681-687.
[29] Sun M,Chen L,Liu H,et al.Association of the S2 allele of the SstI polymorphism in the apoC3 gene with plasma apoCIII interacts with unfavorable lipid profiles to contribute to atherosclerosis in the Li ethnic group in China[J].Lipids Health Dis,2017,16(1):220.
[30] Chen L,Sun M,Liu H,et al.Association of plasma apolipoprotein CIII,high sensitivity C-reactive protein and tumor necrosis factor-alpha contributes to the clinical features of coronary heart disease in Li and Han ethnic groups in China[J].Lipids Health Dis,2018,17(1):176.
[31] Qamar A,Khetarpal SA,Khera AV,et al.Plasma apolipoprotein C-III levels,triglycerides,and coronary artery calcification in type 2 diabetics[J].Arterioscler Thromb Vasc Biol,2015,35(8):1880-1888.
[32] Cui F,Li K,Li Y,et al.Apolipoprotein C3 genetic polymorphisms are associated with lipids and coronary artery disease in a Chinese population[J].Lipids Health Dis,2014,13:170.
[33] Lin B,Huang Y,Zhang M,et al.Association between apolipoprotein C3 Sst I,T-455C,C-482T and C1100T polymorphisms and risk of coronary heart disease[J].BMJ Open,2014,4(1):e004156.
[34] Sesso HD,Lee IM,Gaziano JM,et al.Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women[J].Circulation,2001,104(4):393-398.
[35] Hu SL,Cui GL,Huang J,et al.An APOC3 3'UTR variant associated with plasma triglycerides levels and coronary heart disease by creating a functional miR-4271 binding site[J].Sci Rep,2016,6:32700.
[36] Khetarpal SA,Zeng X,Millar JS,et al.A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels[J].Nat Med,2017,23(9):1086-1094.
[2] Van Der Vliet HN,Sammels MG,Leegwater AC,et al.Apolipoprotein A-V:a novel apolipoprotein associated with an early phase of liver regeneration[J].J Biol Chem,2001,276(48):44512-44520.
[3] Pennacchio LA,Olivier M,Hubacek JA,et al.An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing[J].Science,2001,294(5540):169-173.
[4] Havel RJ.Triglyceride-rich lipoproteins and plasma lipid transport[J].Arterioscler Thromb Vasc Biol,2010,30(1):9-19.
[5] O′brien PJ,Alborn WE,Sloan JH,et al.The novel apolipoprotein A5 is present in human serum,is associated with VLDL,HDL,and chylomicrons,and circulates at very low concentrations compared with other apolipoproteins[J].Clin Chem,2005,51(2):351-359.
[6] 何成毓,李洁琪.血清载脂蛋白A5与冠心病的关系[J].临床心血管杂志,2008,24(12):948-949.
[7] 杨轶文,陈焕芹,常静,等.冠心病患者血清载脂蛋白A5的变化及其与血脂和脂蛋白的关系[J].中国动脉硬化杂志,2006,14(12):1049-1052.
[8] 魏红霞,张葵,邱方,等.血清载脂蛋白 A5 水平与冠心病的关系[J].临床检验杂志,2010,28(7):276-278.
[9] 刘欢,李向平,赵水平,等.冠心病患者载脂蛋白A5与脂联素和空腹胰岛素的关系研究[J],中国实用内科杂志,2007,27(22):1767-1769.
[10] Cui G,Li Z,Li R,et al.A functional variant in APOA5/A4/C3/A1 gene cluster contributes to elevated triglycerides and severity of CAD by interfering with microRNA 3201 binding efficiency[J].J Am Coll Cardiol,2014,64(3):267-277.
[11] Kim M,Kim M,Yoo HJ,et al.A promoter variant of the APOA5 gene increases atherogenic LDL levels and arterial stiffness in hypertriglyceridemic patients[J].PLoS One,2017,12(12):e0186693.
[12] Takeuchi F,Isono M,Katsuya T,et al.Association of genetic variants influencing lipid levels with coronary artery disease in Japanese individuals[J].PLoS One,2012,7(9):e46385.
[13] Lin YC,Nunez V,Johns R,et al.APOA5 Gene Polymorphisms and Cardiovascular Diseases:Metaprediction in Global Populations[J].Nurs Res,2017,66(2):164-174.
[14] You Y,Wu YH,Zhang Y,et al.Effects of polymorphisms in APOA5 on the plasma levels of triglycerides and risk of coronary heart disease in Jilin,northeast China:a case-control study[J].BMJ Open,2018,8(6):e020016.
[15] Wang Y,Lu Z,Zhang J,et al.The APOA5 rs662799 polymorphism is associated with dyslipidemia and the severity of coronary heart disease in Chinese women[J].Lipids Health Dis,2016,15(1):170.
[16] Shou W,Wang Y,Xie F,et al.A functional polymorphism affecting the APOA5 gene expression is causally associated with plasma triglyceride levels conferring coronary atherosclerosis risk in Han Chinese Population[J].Biochim Biophys Acta,2014,1842(11):2147-2154.
[17] Kashyap S,Kumar S,Agarwal V,et al.The association of polymorphic variants,rs2267788,rs1333049 and rs2383207 with coronary artery disease,its severity and presentation in North Indian population[J].Gene,2018,648:89-96.
[18] Soufi M,Sattler AM,Kurt B,et al.Mutation screening of the APOA5 gene in subjects with coronary artery disease[J].J Investig Med,2012,60(7):1015-1019.
[19] 王瑾瑜.载脂蛋白CIII与高甘油三酯血症[J].生理科学进展,2010,41(1):37-39.
[20] Yang G,Lei MM,Yu CL,et al.Apolipoprotein A5 and apolipoprotein C3 single nucleotide polymorphisms are correlated with an increased risk of coronary heart disease:a case-control and meta-analysis study[J].Lipids Health Dis,2015,14:113.
[21] Sacks FM,Alaupovic P,Moye LA,et al.VLDL,apolipoproteins B,CIII,and E,and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial[J].Circulation,2000,102(16):1886-1892.
[22] Aroner SA,Koch M,Mukamal KJ,et al.High-Density Lipoprotein Subspecies Defined by Apolipoprotein C-III and Subclinical Atherosclerosis Measures:MESA (The Multi-Ethnic Study of Atherosclerosis)[J].J Am Heart Assoc,2018,7(6):e007824.
[23] Manfredi M,Chiariello C,Conte E,et al.Plasma proteome profiles of stable CAD patients stratified according to total apo C-III levels[J].Proteomics Clin Appl,2019,13(3):e1800023.
[24] Luo M,Su X,Yi Y,et al.Apolipoprotein CIII may mediate the impacts of angiopoietin-like protein 8 on triglyceride metabolism[J].Lipids Health Dis,2018,17(1):160.
[25] Xiong X,Liu H,Hua L,et al.The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it[J].Lipids Health Dis,2015,14:127.
[25] Luo M,Liu A,Wang S,et al.ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity[J].Sci Rep,2017,7(1):2312.
[27] Kawakami A,Aikawa M,Libby P,et al.Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells[J].Circulation,2006,113(5):691-700.
[28] Kawakami A,Aikawa M,Alcaide P,et al.Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells[J].Circulation,2006,114(7):681-687.
[29] Sun M,Chen L,Liu H,et al.Association of the S2 allele of the SstI polymorphism in the apoC3 gene with plasma apoCIII interacts with unfavorable lipid profiles to contribute to atherosclerosis in the Li ethnic group in China[J].Lipids Health Dis,2017,16(1):220.
[30] Chen L,Sun M,Liu H,et al.Association of plasma apolipoprotein CIII,high sensitivity C-reactive protein and tumor necrosis factor-alpha contributes to the clinical features of coronary heart disease in Li and Han ethnic groups in China[J].Lipids Health Dis,2018,17(1):176.
[31] Qamar A,Khetarpal SA,Khera AV,et al.Plasma apolipoprotein C-III levels,triglycerides,and coronary artery calcification in type 2 diabetics[J].Arterioscler Thromb Vasc Biol,2015,35(8):1880-1888.
[32] Cui F,Li K,Li Y,et al.Apolipoprotein C3 genetic polymorphisms are associated with lipids and coronary artery disease in a Chinese population[J].Lipids Health Dis,2014,13:170.
[33] Lin B,Huang Y,Zhang M,et al.Association between apolipoprotein C3 Sst I,T-455C,C-482T and C1100T polymorphisms and risk of coronary heart disease[J].BMJ Open,2014,4(1):e004156.
[34] Sesso HD,Lee IM,Gaziano JM,et al.Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women[J].Circulation,2001,104(4):393-398.
[35] Hu SL,Cui GL,Huang J,et al.An APOC3 3'UTR variant associated with plasma triglycerides levels and coronary heart disease by creating a functional miR-4271 binding site[J].Sci Rep,2016,6:32700.
[36] Khetarpal SA,Zeng X,Millar JS,et al.A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels[J].Nat Med,2017,23(9):1086-1094.